News
TipRanks on MSN1d
BioAtla presents Phase 2 Oz-V clinical trial data at ASCO 2025BioAtla (BCAB) announced data in a poster titled, “Phase 2 Trial of Ozuriftamab Vedotin, a Conditionally Binding CAB-ROR2-ADC, in Patients with ...
The resources in this content pack are designed to encourage learners to explore, analyze, and discuss the importance of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback